HighTower Advisors
LGND icon

HighTower Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

HighTower Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-641
Closed -$11K – 2621
2020
Q2 		$11K Buy
+641
New +$40.6K ﹤0.01% 2305

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's LGND Position: Q2 2026 in Review

HighTower Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 26% in Q2 2026, selling an estimated $671K and leaving 8,284 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

HighTower Advisors first reported a position in LGND in Q3 2017 and has held it in 26 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • HighTower Advisors held 8,284 shares of Ligand Pharmaceuticals worth $2.62M as of Q2 2026.
  • HighTower Advisors sold 2,849 Ligand Pharmaceuticals shares in Q2 2026, an estimated $671K.
  • Ligand Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1602 holding.
  • HighTower Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 26 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.